Artan Dozda Metilfenidat ile Tedavi Edilen Bir Erkek Ergende Oluşan Geçici Hematüri

Bu yazıda, ozmotik kontrollü salınım oral uygulama sistemi-metilfenidat (MF) tedavisindeki doz artırımının ardından iç çamaşırında kanlı lekeler fark eden bir erkek ergen sunulmuştur. Bu belirti, MF tedavisinin kesilmesiyle kaybolmuş, atomoksetin monoterapisi ile ortaya çıkmamış, ancak atomoksetin ve artırılmış dozdaki hızlı salınımlı MF kombinasyonuyla yeniden ortaya çıkmıştır. Bu klinik tablo ve olumsuz etkinin olası patofizyolojik mekanizmaları tartışılmıştır.

Transient Hematuria in an Adolescent Male Treated with Increased Doses of Methylphenidate

In this report we presented the case of an adolescent male who noticed bloody spots on hisunderwear after the dose increase during his osmotic-controlled release oral delivery systemmethylphenidate (MPH) treatment. This symptom disappeared when the MPH treatment wasdiscontinued, was not reported with atomoxetine monotherapy, but reoccurred with combination treatment using atomoxetine and increased doses of immediate-release MPH. We discussedthe clinical picture and the possible pathophysiological mechanisms for this adverse effect.

PDF

___

1. Green WH. Child and Adolescent Clinical Psychopharmacology, 4. ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
2. Coskun M, Zoroglu S. Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol. 2008;28(6):723–5.
3. Coskun M, Zoroglu S. A report of two cases of sexual side effects with OROS methylphenidate. J Child lesc Psychopharmacol. 2009;19(4):477–9.
4. Coskun M, Adak I. Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2017;37(5):637–9.
5. Coskun M. Methylphenidate induced obsessive-compulsive symptoms treated with sertraline. Bull Clin Psychopharmacol. 2011;21(3):274.
6. Coskun M, Adak I, Akaltun I. Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine. J Clin Psychopharmacol. 2014;34(4):537–8.
7. Coskun M, Kaya I. Painful muscle cramps possibly associated with withdrawal from methylphenidate. J Child Adolesc Psychopharmacol. 2016;26(7):658–9.
8. Adak I, Coskun M. Symptomatic cholelithiasis associated with combined use of methylphenidate and fluoxetine in an otherwise healthy adolescent girl. Bull Clin Psychopharmacol. 2017;27(1):101.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
10. Avellino GJ, Bose S, Wang DS. Diagnosis and management of hematuria. Surg Clin North Am. 2016;96(3):503– 51.
11. Kuperman AA, Yaniv I, Stahl B, Tamary H. Methylphenidate as a possible cause of thrombocytopenia. Ann Pharmacother. 2003;37(7–8):1146.
12. Prabhuswamy M, Srinath S, Girimaji S, Seshadri S. Methylphenidate and hypertension. J Child Adolesc Psychopharmacol. 2006;16(6):805–6.
13. Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology. 2003;166(3):264–70.
14. Yesilkaya B, Alli N, Artuz RF, Ulu E, Kartal D, Cinar SL. The frequency of hematuria in acne vulgaris patients during isotretinoin treatment. Cutan Ocul Toxicol. 2017;36(1):74–6.
15. Taj A, Vijendra D, Shafiq Q, Mohamed I. Carboplatininduced hematuria in a patient of breast carcinoma. A case report. Am J Ther. 2011;18(6):e269–e270.